Profluent and Lilly Announce $2.25 Billion Genetic Medicine Deal

Profluent has signed a partnership agreement with pharmaceutical giant Eli Lilly in the field of genetic medicine, with a potential value of up to $2.25 billion. According to Reuters, under the agreement, Profluent will develop innovative technologies for the treatment of genetic diseases. Under the financial terms of the deal, Profluent will receive an upfront payment upon signing and will be eligible for additional payments upon achieving certain clinical, regulatory, and commercial milestones. The total potential value was announced as $2.25 billion. The partnership aims to expand Lilly's portfolio using Profluent's gene editing and gene therapy platforms, with a particular focus on rare diseases and chronic conditions of genetic origin. This collaboration is seen as a sign of major pharmaceutical companies' growing interest in genetic medicine. Industry experts suggest that such deals may increase in the coming period. This is not investment advice.

📊 GOOGL — Piyasa Yorumu

▲ up · 65%

GOOGL shares closed at $387.76, trading above its 20-day SMA of $385.15, maintaining a short-term uptrend. The RSI at 67.25 is approaching overbought territory but is not yet at dangerous levels, suggesting momentum could continue. Although the MACD remains below the signal line, it is still in positive territory, which may indicate a weakening bullish trend. The headline news of a major genetics medicine deal could positively reflect on Alphabet's investments in healthcare and artificial intelligence, providing short-term support for the stock. However, given the elevated RSI and the MACD signal crossover, an upward move can be expected with cautious optimism.

RSI 14

67.3

MACD

4.86

24h Δ

0.82%

📊 LLY — Piyasa Yorumu

▲ up · 70%

Eli Lilly (LLY) shares closed at $989.77, up 5.2% following news of a $2.25 billion genetic medicine deal. While the RSI has entered overbought territory at 76, the MACD remains positive above its signal line. The short-term trend is strong, but overbought conditions pose a risk of slowing momentum. Therefore, the upside outlook is maintained with medium-to-high confidence.

RSI 14

76.2

MACD

18.11

24h Δ

5.25%

Canlı Grafikler